A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study).

@article{Legutko2013ACE,
  title={A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study).},
  author={Jacek Legutko and Wojciech Zasada and Grzegorz L Kałuża and Grzegorz Heba and Lukasz Rzeszutko and Jacek Jakala and Jacek Dragan and Artur Klecha and Dawid Giszterowicz and Wojciech Dobrowolski and Lukasz Partyka and Swaminathan Jayaraman and Dariusz Dudek},
  journal={Indian heart journal},
  year={2013},
  volume={65 4},
  pages={388-94}
}
AIMS Evaluation of safety and efficacy of ProNOVA XR, a new generation of polymer-free sirolimus eluting stents (SES), utilizing a pharmaceutical excipient for timed release of sirolimus from the XR platform. METHODS AND RESULTS Safety and efficacy of ProNOVA XR coronary stent system was examined in EURONOVA prospective, single arm, multi-center registry of 50 patients with de novo native coronary lesions up to 28 mm in length in arteries between 2.25 and 4 mm. At 6-month, in-stent late lumen… CONTINUE READING